Brianne Langa is a corporate associate in the Boston office of Kirkland & Ellis LLP. Her practice focuses on mergers and acquisitions for public and private companies primarily in the pharmaceutical, biotechnology and technology industries.
Experience
Representative Matters
Prior to joining Kirkland, Brianne was involved in the following representations:
SiteOne Therapeutics in its acquisition by Eli Lilly for up to $1 billion
The special committee of the board of directors of AspenTech in its $7.2 billion sale to Emerson Electric of all shares of AspenTech not already owned by Emerson
EyeBio in its sale to Merck for $1.3 billion up front and up to $1.7 billion in future milestone payments
The special committee of the board of directors of EngageSmart in its $4 billion sale to Vista Equity Partners
Mirati Therapeutics in its sale to Bristol Myers Squibb for up to $5.8 billion
POINT Biopharma in its $1.4 billion acquisition by Eli Lilly
IVERIC Bio in its $5.9 billion sale to Astellas
Kelso & Company in its sale of Refresh Mental Health to Optum, a division of UnitedHealthcare
Dicerna Pharmaceuticals in its sale to Novo Nordisk for $3.3 billion
Prior Experience
Skadden, Arps, Slate, Meagher & Flom LLP
More
Credentials
Admissions & Qualifications
2021Massachusetts
Education
Boston University School of LawJ.D.magna cum laude2021
Boston University Law Review
University of Colorado at BoulderB.A., Anthropology & Sociology2018
